

Press Release

Dr. Rico Buchli Joins Pure Protein L.L.C.

OKLAHOMA CITY and AUSTIN, Texas, July 20, 2001- Emergent Technologies, Inc. (ETI) announced that Rico Buchli, Ph.D, has joined one of its portfolio companies, Pure Protein, LLC, as Director of Research, continuing Pure Protein's work in the area of soluble HLA molecule identification and production. Dr. Buchli joins Chief Scientist, William Hildebrand, Ph.D, at Pure Protein, a two year old biomedical company located at the Oklahoma Health Center Research Park which uses patented, breakthrough genetic engineering processes to manufacture proteins for use in organ transplantation diagnostic kit development, autoimmune disorder therapeutics, and vaccine development. www.pureproteinllc.com

Formerly a Postdoctoral researcher at the University of California, Davis, Dr. Buchli's research in immunology has centered around identification of molecules involved in metastatic cancers which can be used in developing therapies targeted towards specific kinds of tumors. Dr. Buchli earned his Ph.D in Biochemistry at the University of Basel, Switzerland, completing his doctoral thesis at Hoffmann-La Roche AG in Basel.

Pure Protein was one of the first companies founded on technology developed at the OU Health Sciences Center. The technology was licensed in 1999 by ETI, an Austin-based investment and management company with offices in Oklahoma City, in an agreement giving OU an equity and royalty stream position in the company. Pure Protein is currently partnering with LifeCodes, a pharmaceutical company headquartered in Stamford, CN, developing organ transplantation kits which will predict hyper-acute organ rejection in transplant patients. Negotiations are also underway with an as yet undisclosed pharmaceutical partner to jointly design the next generation of vaccines for use in the treatment of cancer, AIDS, hepatitis, and autoimmune diseases such as arthritis, diabetes and multiple sclerosis. Tommy Harlan, CEO and Founder of ETI, noted, "We are extremely fortunate to have a researcher of Dr. Buchli's stature and accomplishment join our research team. His work along with Dr. Hildebrand's will move Pure Protein even faster along in meeting its scientific milestones and spur its development as one of Oklahoma's premier biomedical companies."

From patent, prototype and test phases of development, ETI accelerates the commercialization process by identifying new markets and appropriate industry or corporate partners. For more information, visit the ETI website at www.emergenttechnologies.com or contact James Ehrlich, Vice President, Capital Acquisitions and Investor Relations, at jehrich@emergenttechnologies.com or 512/263-3232.